CRP and neoplasm: In this regard, our analysis suggests that, in addition to classical prognostic factors such as low Hb, high neutrophil/lymphocyte ratio, high ALP, and high CRP, baseline evaluation of tumor burden according to more sophisticated surrogate markers such as WB-MATV, cfDNA and CTCs may help to refine prognostication and eventually guide decision regarding trial recruitment.